-
Signature
-
/s/ Avraham S. Adler, Attorney-in-Fact
-
Stock symbol
-
PTCT
-
Transactions as of
-
Sep 11, 2025
-
Transactions value $
-
-$1,090,400
-
Form type
-
4
-
Date filed
-
9/15/2025, 05:00 PM
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Boulding Mark Elliott |
EXEC. VP AND CLO |
C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN |
/s/ Avraham S. Adler, Attorney-in-Fact |
2025-09-15 |
0001578852 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$680K |
+17.8K |
+17.17% |
$38.10 |
122K |
Sep 11, 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$1.09M |
-17.8K |
-14.65% |
$61.00 |
104K |
Sep 11, 2025 |
Direct |
F1, F2 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$89.8K |
+2.36K |
+2.27% |
$38.10 |
106K |
Sep 11, 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$144K |
-2.36K |
-2.22% |
$61.00 |
104K |
Sep 11, 2025 |
Direct |
F1, F3 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$94.1K |
+2.47K |
+2.38% |
$38.10 |
106K |
Sep 11, 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$151K |
-2.47K |
-2.32% |
$61.00 |
104K |
Sep 11, 2025 |
Direct |
F1, F4 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$863K |
+22.7K |
+21.81% |
$38.10 |
127K |
Sep 12, 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$1.36M |
-22.1K |
-17.48% |
$61.33 |
104K |
Sep 12, 2025 |
Direct |
F1, F5 |
| transaction |
PTCT |
Common Stock |
Sale |
-$33.8K |
-544 |
-0.52% |
$62.09 |
104K |
Sep 12, 2025 |
Direct |
F1, F6 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$38.8K |
+1.02K |
+0.98% |
$38.10 |
105K |
Sep 12, 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$62.5K |
-1.02K |
-0.97% |
$61.31 |
104K |
Sep 12, 2025 |
Direct |
F1, F7 |
| transaction |
PTCT |
Common Stock |
Options Exercise |
$34.5K |
+905 |
+0.87% |
$38.10 |
105K |
Sep 12, 2025 |
Direct |
F1 |
| transaction |
PTCT |
Common Stock |
Sale |
-$55.4K |
-905 |
-0.86% |
$61.21 |
104K |
Sep 12, 2025 |
Direct |
F1, F8 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-17.8K |
-33.03% |
$0.00 |
36.2K |
Sep 11, 2025 |
Common Stock |
17.8K |
$38.10 |
Direct |
F1, F9 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-2.36K |
-6.52% |
$0.00 |
33.8K |
Sep 11, 2025 |
Common Stock |
2.36K |
$38.10 |
Direct |
F1, F9 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-2.47K |
-7.31% |
$0.00 |
31.3K |
Sep 11, 2025 |
Common Stock |
2.47K |
$38.10 |
Direct |
F1, F9 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-22.7K |
-72.32% |
$0.00 |
8.68K |
Sep 12, 2025 |
Common Stock |
22.7K |
$38.10 |
Direct |
F1, F9 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-1.02K |
-11.75% |
$0.00 |
7.66K |
Sep 12, 2025 |
Common Stock |
1.02K |
$38.10 |
Direct |
F1, F9 |
| transaction |
PTCT |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-905 |
-11.82% |
$0.00 |
6.75K |
Sep 12, 2025 |
Common Stock |
905 |
$38.10 |
Direct |
F1, F9 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: